Biosimilar Drugs for Multiple Sclerosis: An Unmet International Need or a Regulatory Risk?
Crossref DOI link: https://doi.org/10.1007/s40120-019-0145-0
Published Online: 2019-07-16
Published Print: 2019-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Rivera, Victor M.
Text and Data Mining valid from 2019-07-16
Version of Record valid from 2019-07-16
Article History
Received: 27 June 2019
First Online: 16 July 2019